Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

NCT00376584 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

825

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesteremia
Hyperlipidemia

Interventions

DRUG: MK-0524A
DRUG: ER Niacin
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC